CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

DesidustatWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)

Name (Synonyms) Correlation
drug737 Delayed diagnostics Anyplex TMII RV16 Detection Wiki 1.00
drug2028 Rapid diagnostics using Anyplex TMII RV16 Detection Wiki 1.00
drug2319 Standard of Care Wiki 0.20

Correlated MeSH Terms (3)

Name (Synonyms) Correlation
D005335 Fever of Unknown Origin NIH 1.00
D002637 Chest Pain NIH 1.00
D004417 Dyspnea NIH 0.38

Correlated HPO Terms (2)

Name (Synonyms) Correlation
HP:0100749 Chest pain HPO 1.00
HP:0002098 Respiratory distress HPO 0.38

There is one clinical trial.

Clinical Trials

1 A Phase 2b, Multicenter, Open-label, Randomized, Comparator-Controlled, Study to Evaluate the Efficacy and Safety of Desidustat Tablet for the Management of COVID-19 Patients

This study is a Phase 2b, Multicenter, Open-label, Randomized, Comparator- Controlled Study to Evaluate the Efficacy and Safety of Desidustat Tablet for the Management of mild, moderate and severe COVID-19 patients. 100 mg of Desidustat will be administered for a period of 14 days along with recommended standard care during the trial.

NCT04463602 COVID-19 Drug: Desidustat Other: Standard of Care

Primary Outcomes

Description: Not hospitalized, no limitations on activities. Not hospitalized, limitation on activities. Hospitalized, not requiring supplemental oxygen. Hospitalized, requiring supplemental oxygen. Hospitalized, on non-invasive ventilation or high flow oxygen devices. Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO). Death.

Measure: Change in Clinical status of subject on a 7-point ordinal scale

Time: Week 2

Secondary Outcomes

Description: PCR for SARS-CoV-2 in pharyngeal swab

Measure: PCR test

Time: Week 2 and Week 4

Description: Occurrence of supplemental Oxygen

Measure: Supplemental Oxygen

Time: Week 2 and Week 4

Description: Occurrence of Mechanical Ventilation

Measure: Mechanical Ventilation

Time: Week 2 and Week 4

Description: Occurence of Adverse events

Measure: Incidence of Treatment-Emergent Adverse Events

Time: Week 2 and Week 4

Description: Laboratory Assessments

Measure: Laboratory Assessments

Time: Week 2 and Week 4

Description: Inflammatory Biomarker

Measure: C-reactive protein (CRP)

Time: Week 2 and Week 4

Description: Inflammatory Biomarker

Measure: Interleukin 6 (IL-6)

Time: Week 2 and Week 4

Description: Inflammatory Biomarker

Measure: D-dimer

Time: Week 2 and Week 4

No related HPO nodes (Using clinical trials)